Check out our affiliate for an innovative technology to monitor the effect of IC therapy.

Ischemic Conditioning Therapy: Webinar Event Prior to AHA 2015

Ischemic Conditioning Therapy:

A Powerful Therapy Awaiting Clinical Adoption

Overview and Updates on Clinical Trials

A webinar event prior to the 2015 Annual Scientific Session of the American Heart Association




Webinar ID:  115-613-699

Click Here to Watch Recorded Webinar

Event Date: Tuesday, November 3, 2015  (Add to calendar)

Event Time: 12:00 - 2:00 PM, PST

*This educational event is organized by: Ischemic Conditioning Therapeutics, Inc. ( and is not part of unofficial AHA satellite events.



    Morteza Naghavi, M.D.
Dr. Naghavi is the founder and president of MEDITEX, a medical technology innovation and investment company dedicated to translating innovative ideas to healthcare solutions. He is also the Founder and Executive Chairman of the Society for Heart Attack Prevention and Eradication (SHAPE) based in Houston, Texas. Dr. Naghavi received his MD from Tehran University of Medical Sciences and was trained at the University of Texas Health Science Center in Houston and Texas Heart Institute where he served as a cardiology faculty member and Co-Director of the Vulnerable Plaque Research Department. Dr. Naghavi led advancing the field of “Vulnerable Plaque” to “Vulnerable Patient” and organized the SHAPE Task Force to focus on early detection and treatment of asymptomatic patients with subclinical atherosclerosis through the SHAPE Guidelines. He has over 30 inventions in the fields of interventional cardiology, noninvasive imaging, ambulatory diagnostics, wearable sensors, and personalized preventive healthcare. Among his inventions are digital thermal monitoring of vascular function and personalized ischemic conditioning device. Dr. Naghavi has numerous publications and is the editor of Asymptomatic Atherosclerosis; Pathophysiology,Detection and Treatment.





Presenter 1:

Download PPT Slides

Karen Przyklenk Ph.D.
Professor and Director of the Cardiovascular Research Institute, Wayne State University School of Medicine, Detroit, MI. is Director of the Cardiovascular Research Institute and Professor of Physiology and Emergency Medicine at Wayne State University School of Medicine. Dr. Przyklenk has more than 20 years of experience in conducting translational, bench-to-bedside research focusing on the pathophysiology of acute coronary ischemic syndromes, the identification of cellular mechanisms and signaling pathways that increase the tolerance of the myocardium to ischemia, and the development of novel strategies to limit damage caused to the heart by ischemiareperfusion. Dr. Przyklenk' has authored more than 170 peer-reviewed papers, invited reviews, editorials and book chapters in the field of myocardial ischemia and infarction, is on the editorial board of multiple journals, and been a grant reviewer for the NIH, the American Heart Association, as well as the Biomedical Research Council of Singapore and the Wellcome Trust (UK). In addition to her research interests, one of Dr. Przyklenk's long-standing priorities has been the mentoring of post-doctoral fellows and junior faculty; indeed, several of her previous mentees have become established, independent scientists and leaders in cardiovascular research.


Presenter 2:


Download PPT Slides 

Robert A. Kloner, M.D., Ph.D.
Dr. Kloner is the Director of Cardiovascular Research Institute and Vice President of Translation at the Huntington Medical Research Institutes in Pasadena, CA. and Professor of Clinical Medicine at the Keck School of Medicine at University of Southern California in Los Angeles. Dr. Kloner received his MD and PhD degrees from Northwestern University Medical School in Chicago and clinical and research fellowships in medicine and cardiology at Harvard Medical School and Brigham and Women’s Hospital where he served as Assistant and then Associate Professor. Among Dr. Kloner’s major research interests are protection of ischemic myocardium, development of therapies for limiting myocardial infarct size. He has participated in studies funded by the National Institutes of Health on cardiac cell transplantation, doxorubicin cardiomyopathy, functional analysis of cardiac grafts, and stem cells. Dr.Kloner has contributed over 683 original papers in peer-reviewed journals; over 217 chapters or monographs and over 497 abstracts. Dr. Kloner is the author and editor of 18 medical texts including: Ischemic Preconditioning, Cardiovascular Trials Reviews (10 editions), and The Guide to Cardiology (3 editions). Dr. Kloner is known as the pioneer in the field of remote ischemic conditioning.